Biotronik in first coronary implant of absorbable stent:
This article was originally published in Clinica
Biotronik has taken a step forward in its bid to take its absorbable metal stent (AMS) to the coronary artery disease market. It has conducted the first human implant of the device, as part of its PROGRESS-AMS study. The product's safety has already been confirmed in below-the-knee arteries - the first human implant for this indication took place in December 2003, said the Berlin, Germany firm. Commenting on the coronary implant, the company said that four-month follow-up would be needed to determine the potential of the technology and to validate its expectations of moving the technology into the boundaries of coronary stenting.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.